This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1988:32:128-53.

doi: 10.1159/000414676.

Adoptive immunotherapy in combination with chemotherapy for cancer treatment

R H Wiltrout, R R Salup

PMID: 3287448
DOI: 10.1159/000414676

Review

Adoptive immunotherapy in combination with chemotherapy for cancer treatment

R H Wiltrout et al. Prog Exp Tumor Res. 1988.

. 1988:32:128-53.

doi: 10.1159/000414676.

Authors

R H Wiltrout, R R Salup

PMID: 3287448
DOI: 10.1159/000414676

No abstract available

PubMed Disclaimer

Similar articles

Therapeutic requirements for the successful treatment of murine renal carcinoma by adoptive chemoimmunotherapy.
Wiltrout RH, Mathieson BJ, Back TC, Salup RR. Wiltrout RH, et al. Prog Clin Biol Res. 1987;244:17-25. Prog Clin Biol Res. 1987. PMID: 3498946 No abstract available.
Models of adoptive T-cell-mediated regression of established tumors.
North RJ. North RJ. Contemp Top Immunobiol. 1984;13:243-57. doi: 10.1007/978-1-4757-1445-6_12. Contemp Top Immunobiol. 1984. PMID: 6610533 No abstract available.
Genetically engineered vaccines. Comparison of active versus passive immunotherapy against solid tumors.
Koeppen H, Singh S, Schreiber H. Koeppen H, et al. Ann N Y Acad Sci. 1993 Aug 12;690:244-55. doi: 10.1111/j.1749-6632.1993.tb44013.x. Ann N Y Acad Sci. 1993. PMID: 8368742
Therapy of disseminated tumors by adoptive transfer of specifically immune T cells.
Greenberg PD, Klarnet JP, Kern DE, Cheever MA. Greenberg PD, et al. Prog Exp Tumor Res. 1988;32:104-27. doi: 10.1159/000414675. Prog Exp Tumor Res. 1988. PMID: 3287447 Review. No abstract available.
The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Ettinghausen SE, Rosenberg SA. Ettinghausen SE, et al. Springer Semin Immunopathol. 1986;9(1):51-71. Springer Semin Immunopathol. 1986. PMID: 3523804 Review. No abstract available.

See all similar articles

Cited by

Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon alpha and the role of specific T cells.
Kedar E, Rutkowski Y, Leshem B. Kedar E, et al. Cancer Immunol Immunother. 1992;35(1):63-8. doi: 10.1007/BF01741057. Cancer Immunol Immunother. 1992. PMID: 1611625 Free PMC article.
Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type.
Kedar E, Ben-Aziz R, Epstein E, Leshem B. Kedar E, et al. Cancer Immunol Immunother. 1989;29(1):74-8. doi: 10.1007/BF00199920. Cancer Immunol Immunother. 1989. PMID: 2785003 Free PMC article.
Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
Gazit Z, Weiss DW, Shouval D, Yechezkeli M, Schirrmacher V, Notter M, Walter J, Kedar E. Gazit Z, et al. Cancer Immunol Immunother. 1992;35(2):135-44. doi: 10.1007/BF01741861. Cancer Immunol Immunother. 1992. PMID: 1596937 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- S. Karger AG, Basel, Switzerland
Medical
- MedlinePlus Health Information